CTI BIOPHARMA CORP's ticker is CTIC and the CUSIP is 12648L601. A total of 40 filers reported holding CTI BIOPHARMA CORP in Q3 2020. The put-call ratio across all filers is 0.21 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $62 | -54.1% | 14,801 | -34.2% | 0.00% | – |
| Q4 2022 | $135 | -99.9% | 22,489 | -44.3% | 0.00% | – |
| Q3 2022 | $234,000 | -59.0% | 40,371 | -57.9% | 0.00% | -100.0% |
| Q2 2022 | $571,000 | -22.8% | 95,799 | -39.6% | 0.00% | 0.0% |
| Q1 2022 | $740,000 | +264.5% | 158,481 | +93.0% | 0.00% | – |
| Q4 2021 | $203,000 | +968.4% | 82,126 | +1128.0% | 0.00% | – |
| Q1 2021 | $19,000 | – | 6,688 | +411.3% | 0.00% | – |
| Q4 2020 | $0 | – | 1,308 | +1276.8% | 0.00% | – |
| Q3 2020 | $0 | -100.0% | 95 | -98.6% | 0.00% | – |
| Q1 2019 | $6,000 | -94.3% | 6,997 | -85.7% | 0.00% | – |
| Q3 2018 | $105,000 | +1650.0% | 48,819 | +3808.6% | 0.00% | – |
| Q2 2018 | $6,000 | +200.0% | 1,249 | +67.7% | 0.00% | – |
| Q2 2017 | $2,000 | – | 745 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 4,068,191 | $4,719,000 | 9.14% |
| CAXTON CORP | 619,460 | $719,000 | 0.76% |
| BVF INC/IL | 6,929,690 | $8,038,000 | 0.50% |
| NEA Management Company, LLC | 7,140,450 | $8,283,000 | 0.33% |
| Orbimed Advisors | 9,520,600 | $11,044,000 | 0.16% |
| Renaissance Technologies | 2,103,792 | $2,440,000 | 0.00% |
| Paloma Partners Management Co | 30,289 | $35,000 | 0.00% |
| WEDBUSH SECURITIES INC | 12,600 | $15,000 | 0.00% |
| HRT FINANCIAL LP | 19,710 | $22,000 | 0.00% |
| FIRST MANHATTAN CO. LLC. | 33 | $0 | 0.00% |